MDx/CDx Focus: Crescendo's Vectra DA Gets Medicare Coverage; Cobas HPV Test Supplemental PMA | GenomeWeb

Crescendo Garners Medicare Coverage for Vectra DA

Medicare contractor Palmetto GBA has agreed to reimburse for Crescendo Bioscience's Vectra DA multi-marker molecular diagnostic that assesses rheumatoid arthritis activity.

Vectra DA is a blood-based test that measures the levels of 12 proteins. Doctors can use this test in conjunction with standard clinical to track disease activity in RA patients. With the national coverage agreement between Crescendo and Palmetto, Vectra DA is now a covered benefit for Medicare beneficiaries.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.